Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CRHBP | P24387 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.51 |
| ▸ | PTPRF | P10586 | 2/20 | 0.51 |
| ▸ | PTPRA | P18433 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239558 | 0.89 | PTPN1 (0.62) | POLBMAPTMEN1KMT2ACRHBP | |
| SCHEMBL2879296 | 0.88 | POLB (0.61) | POLBMAPTMEN1KMT2ACRHBP | |
| SCHEMBL3075700 | 0.81 | POLB (0.71) | POLBMAPTMEN1KMT2ACRHBP | |
| SCHEMBL612106 | 0.80 | PTPN1 (0.48) | POLBMAPTMEN1KMT2ACRHBP | |
| SCHEMBL2157471 | 0.77 | MAPT (0.69) | POLBMAPTMEN1KMT2AKDM4E | |
| SCHEMBL12396015 | 0.77 | POLB (0.73) | POLBMAPTMEN1KMT2ACRHBP | |
| SCHEMBL2874727 | 0.75 | IKBKB (0.67) | POLBMAPTMEN1KMT2APTPN1 | |
| SCHEMBL2158069 | 0.75 | MEN1 (0.54) | POLBMAPTMEN1KMT2ACRHBP | |
| SCHEMBL14209201 | 0.74 | POLB (0.50) | POLBMAPTMEN1KMT2ACRHBP | |
| SCHEMBL17226314 | 0.73 | PTPN1 (0.68) | POLBMAPTMEN1KMT2ACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7402608-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | POLB 3431/4885MAPT 1641/4885MEN1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.